Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Probiotics  COVID-19 treatment studies for Probiotics  C19 studies: Probiotics  Probiotics   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Discharge -12% Improvement Relative Risk Time to discharge -60% Time to viral- -35% Li et al. Probiotics for COVID-19 LATE TREATMENT Is late treatment with probiotics beneficial for COVID-19? Retrospective 311 patients in China Slower viral clearance with probiotics (p=0.001) Li et al., Int. Immunopharmacology, doi:10.1016/j.intimp.2021.107531 Favors probiotics Favors control
The role of probiotics in coronavirus disease-19 infection in Wuhan: A retrospective study of 311 severe patients
Li et al., International Immunopharmacology, doi:10.1016/j.intimp.2021.107531
Li et al., The role of probiotics in coronavirus disease-19 infection in Wuhan: A retrospective study of 311 severe.., International Immunopharmacology, doi:10.1016/j.intimp.2021.107531
Mar 2021   Source   PDF  
  All Studies   Meta
Retrospective 311 severe condition hospitalized patients in China, 123 treated with probiotics, showing slower viral clearance and recovery with treatment. Authors note that probiotics were able to moderate immunity and decrease the incidence of secondary infections.
The immune effects of probiotics are strain-specific.
risk of no hospital discharge, 11.8% higher, RR 1.12, p = 0.68, treatment 30 of 123 (24.4%), control 41 of 188 (21.8%).
time to discharge, 60.0% higher, relative time 1.60, p < 0.001, treatment 123, control 188.
time to viral-, 35.3% higher, relative time 1.35, p < 0.001, treatment 123, control 188.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Li et al., 5 Mar 2021, retrospective, China, peer-reviewed, 7 authors, average treatment delay 13.0 days.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperProbioticsAll
Abstract: Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. International Immunopharmacology 95 (2021) 107531 Contents lists available at ScienceDirect International Immunopharmacology journal homepage: The role of probiotics in coronavirus disease-19 infection in Wuhan: A retrospective study of 311 severe patients Qiang Li 1, Fang Cheng 1, Qiling Xu , Yuyong Su , Xuefeng Cai , Fang Zeng *, Yu Zhang * Department of Pharmacy, Union Hospital, Tongji Medical College, Hua Zhong University of Science and Technology, Wuhan 430022, China Hubei Province Clinical Research Center for Precision Medicine for Critical Illness, Wuhan 430022, China A R T I C L E I N F O A B S T R A C T Keywords: COVID-19 Probiotics Immunity Inflammatory Purpose: Researches revealed that probiotics maybe a potential strategy for COVID-19, whereas there is a lack of related evidence. This study aims to analyze the role of probiotics on severe COVID-19 patients. Methods: In the current retrospective single-center study, we collected data of 311 consecutive severe patients with confirmed COVID-19 in Wuhan Union Hospital from Feb 3rd to Feb 20th, 2020. Epidemiological, clinical and medication characteristics were compared and analyzed between patients with or without probiotics. Results: In total, 93 of the 123 patients (75.61%) who were treated with probiotics survived to hospital discharge with the median inpatient day of 32 days and mean virus clearance time of 23 days, which were significantly longer than those of patients without probiotics. There were no bias in laboratory parameters, except for IL-6 and ESR, which were significantly higher in patients treated probiotics. We tracked the dynamic changes of 8 selected laboratory parameters (IL-6, CRP, total T lymphocytes, NK cells, B lymphocyte, CD4 + T cells, CD8 + T cells and CD4/CD8 ratio) and found that probiotics could not reduce the increased IL-6 levels but possessed the ability to moderate the immunity and decreased the incidence of secondary infection in COVID-19 patients. Conclusions: Probiotics could be an effective strategy for the treatment of COVID-19 patients to reduce the secondary infection and moderated the immunity.
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop